Reference number(s)
2811-H

SPECIALTY QUANTITY LIMIT PROGRAM

XOSPATA (gilteritinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Xospata (gilteritinib) 40 mg tablets	90 per 30 days	Acute Myeloid Leukemia (AML): 120 mg once daily Dose modification for toxicity: 80 mg once daily

III. REFERENCES

1. Xospata [package insert]. Northbrook, IL: Astellas Pharma Inc.; November 2018.

© 2018 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

CVS caremark™